News

Viaskin Peanut is the Company’s lead product candidate designed to potentially reduce the risk of life-threatening allergic reactions due to accidental exposure to peanuts. A non-invasive, once-daily, epicutaneous

The company was founded on computationally designed self-assembling virus-like particle (VLP) technology developed at the Institute for Protein Design (IPD) at University of Washington School of Medicine (Cell

Goldfinch Bio will assume all development and commercialization responsibilities for the treatment of rare and metabolic kidney diseases worldwide. However, the agreement grants Takeda the option, prior to

Descovy for PrEP has been approved to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing minimum 35kg who are HIV-negative and at-risk for

Proceeds from the financing will be used to advance Elicio’s pipeline of novel lymph node targeted immuno-therapies, including ELI-002, an Amphiphile mKRAS vaccine (AMP KRAS). ELI-002 targets all

This new indication was granted full approval based on the overall survival (OS) findings from the Phase 3 KEYNOTE-042 trial, including data from an extension of the global

As per terms of the deal, Progenics shareholders will secure 0.2502 shares of Lantheus stock for each share of Progenics stock, representing around 35% aggregate ownership interest in

Trelegy Ellipta, which is a once-daily, single-inhaler triple therapy, was approved by the US Food and Drug Administration (FDA) in late 2017 for the long-term, once-daily maintenance treatment

Pixuvri has approval for the treatment of adult patients having multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma, a type of blood cancer. The drug is a cytotoxic